Gilead Sciences, Inc. $GILD Shares Acquired by Putney Financial Group LLC

Putney Financial Group LLC increased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 53.4% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 270 shares of the biopharmaceutical company’s stock after purchasing an additional 94 shares during the period. Putney Financial Group LLC’s holdings in Gilead Sciences were worth $30,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently added to or reduced their stakes in the stock. Simon Quick Advisors LLC boosted its position in shares of Gilead Sciences by 210.1% in the second quarter. Simon Quick Advisors LLC now owns 27,392 shares of the biopharmaceutical company’s stock worth $3,037,000 after buying an additional 18,558 shares during the period. Strs Ohio lifted its position in Gilead Sciences by 4.3% during the 2nd quarter. Strs Ohio now owns 534,303 shares of the biopharmaceutical company’s stock worth $59,238,000 after acquiring an additional 22,123 shares in the last quarter. Impact Partnership Wealth LLC lifted its position in Gilead Sciences by 66.2% during the 2nd quarter. Impact Partnership Wealth LLC now owns 13,138 shares of the biopharmaceutical company’s stock worth $1,457,000 after acquiring an additional 5,232 shares in the last quarter. Amalgamated Bank boosted its holdings in Gilead Sciences by 9.2% in the 2nd quarter. Amalgamated Bank now owns 270,927 shares of the biopharmaceutical company’s stock worth $30,038,000 after acquiring an additional 22,916 shares during the period. Finally, Atria Investments Inc grew its position in Gilead Sciences by 22.3% in the second quarter. Atria Investments Inc now owns 79,026 shares of the biopharmaceutical company’s stock valued at $8,762,000 after acquiring an additional 14,392 shares in the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $118.44 on Friday. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. Gilead Sciences, Inc. has a 1 year low of $86.08 and a 1 year high of $124.61. The firm’s 50-day simple moving average is $115.56 and its 200-day simple moving average is $111.48. The firm has a market cap of $146.96 billion, a PE ratio of 23.59, a price-to-earnings-growth ratio of 0.81 and a beta of 0.34.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The business had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.42 billion. During the same period last year, the firm earned $2.02 earnings per share. The company’s revenue for the quarter was up 3.0% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Equities analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 30th. Investors of record on Monday, December 15th will be given a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend is Monday, December 15th. Gilead Sciences’s dividend payout ratio is currently 62.95%.

Insider Buying and Selling

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the stock in a transaction on Friday, August 15th. The shares were sold at an average price of $118.53, for a total transaction of $3,318,840.00. Following the sale, the insider directly owned 114,168 shares of the company’s stock, valued at approximately $13,532,333.04. This represents a 19.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total transaction of $295,200.00. Following the completion of the transaction, the chief financial officer directly owned 157,055 shares of the company’s stock, valued at $18,545,054.40. This trade represents a 1.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 71,500 shares of company stock worth $8,336,040 over the last ninety days. 0.27% of the stock is owned by insiders.

Wall Street Analyst Weigh In

GILD has been the topic of a number of recent research reports. Royal Bank Of Canada boosted their target price on shares of Gilead Sciences from $98.00 to $100.00 and gave the stock a “sector perform” rating in a research report on Wednesday, October 8th. BMO Capital Markets boosted their price objective on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an “outperform” rating in a report on Monday, October 20th. Citigroup raised their target price on Gilead Sciences from $125.00 to $135.00 and gave the company a “buy” rating in a research note on Wednesday, October 8th. Daiwa America raised Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, August 19th. Finally, Rothschild & Co Redburn increased their price target on Gilead Sciences from $136.00 to $143.00 and gave the company a “buy” rating in a report on Friday, September 12th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus price target of $122.61.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.